Information Finerenone Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease. Targets MR (Cell-free assay) 18 nM In vitro Finerenone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. Finerenone significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels. In vivo Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria. Cell Research(from reference) Cell lines：Human coronary artery smooth muscle cells (SMC), human umbilical vein endothelial cells (EC) Concentrations：1 nM, 10 nM Incubation Time：24 h